Raytheon did not specify the distance of the shot—likely in an attempt to hide the AMRAAM’s true capabilities from potential US adversaries.

Newly launched ophthalmology company Ollin Biosciences has emerged onto the scene with $100 million in backing and a mission to bring a rival drug for wet age-related macular degeneration (AMD) that ...